| TA181 |
Lung cancer (non-small-cell, first line treatment) - pemetrexed (TA181) |
|
-
-
lung cancer
Fast, easy summary view of NICE guidance on 'lung cancer'
-
-
-
Pemetrexed for the first-line treatment of non-small-cell lung cancer
Pemetrexed is recommended as a possible treatment for locally advanced or metastatic non-small-cell lung cancer (NSCLC) if:
- the cancer is a particular type (adenocarcinoma or large-cell carcinoma) and
- the person has not had any treatment for NSCLC before.
Healthcare professionals should not stop prescribing pemetrexed for people who do not have adenocarcinoma or large-cell carcinoma who were already taking it when the guidance was issued. These people should be able to carry on taking pemetrexed until they and their specialist decide that it is the right time to stop treatment.
-
Other information
NICE Pathways
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: lung cancer
How this guidance was produced
Background information
This page was last updated: 29 March 2012
-
Guidance formats
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- Patient version (MS Word)
- TA181 Pemetrexed fel triniaeth gyntaf ar gyfer canser yr ysgyfaint lle nad yw'r celloedd yn fach: deall canllawiau NICE
Lung cancer (non-small-cell, first line treatment) - pemetrexed
Guideline for patients and carers (PDF)
-
Implementation tools and resources
See this guidance in practice
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.
